| Jonathan Harris Taylor, MD | |
|
1850 W Arlington Blvd, Greenville, NC 27834 | |
| (252) 413-6678 | |
| (252) 215-2905 |
| Full Name | Jonathan Harris Taylor |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 22 Years |
| Location | 1850 W Arlington Blvd, Greenville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114134780 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 200700626 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vidant Medical Center | Greenville, NC | Hospital |
| Vidant Chowan Hospital | Edenton, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physicians East Pa | 1850284571 | 110 |
News Archive
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal.
A new Aggressive Behavior study has examined alcohol's "in the moment" effects on sexual aggression, or the acute effects of alcohol on men's decisions about how to respond to sexual refusals in a dating simulation.
Leaders at Maryland's top hospitals worry about efforts to cut hospital costs in the health care reform proposals.
› Verified 3 days ago
| Entity Name | Physicians East Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598761967 PECOS PAC ID: 1850284571 Enrollment ID: O20040205001222 |
News Archive
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal.
A new Aggressive Behavior study has examined alcohol's "in the moment" effects on sexual aggression, or the acute effects of alcohol on men's decisions about how to respond to sexual refusals in a dating simulation.
Leaders at Maryland's top hospitals worry about efforts to cut hospital costs in the health care reform proposals.
› Verified 3 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal.
A new Aggressive Behavior study has examined alcohol's "in the moment" effects on sexual aggression, or the acute effects of alcohol on men's decisions about how to respond to sexual refusals in a dating simulation.
Leaders at Maryland's top hospitals worry about efforts to cut hospital costs in the health care reform proposals.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Harris Taylor, MD 1850 W Arlington Blvd, Greenville, NC 27834-5704 Ph: (252) 413-6678 | Jonathan Harris Taylor, MD 1850 W Arlington Blvd, Greenville, NC 27834 Ph: (252) 413-6678 |
News Archive
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal.
A new Aggressive Behavior study has examined alcohol's "in the moment" effects on sexual aggression, or the acute effects of alcohol on men's decisions about how to respond to sexual refusals in a dating simulation.
Leaders at Maryland's top hospitals worry about efforts to cut hospital costs in the health care reform proposals.
› Verified 3 days ago
Dr. Jeffrey B Asbury, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 275 Bethesda Dr, Greenville, NC 27834 Phone: 252-752-5077 | |
Dr. Nathaniel John Williams, DO Urology Medicare: Medicare Enrolled Practice Location: 275 Bethesda Dr, Greenville, NC 27834 Phone: 252-752-5077 | |
Dr. William Foster Rawls, MD, MSCR Urology Medicare: Accepting Medicare Assignments Practice Location: 275 Bethesda Dr, Greenville, NC 27834 Phone: 252-752-5077 | |
Dr. Jonathan Nathaniel Hamilton, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 275 Bethesda Dr, Greenville, NC 27834 Phone: 252-752-5077 Fax: 252-752-9544 | |
Dr. Matthew Alan Collins, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 275 Bethesda Dr, Greenville, NC 27834 Phone: 252-752-5077 Fax: 252-752-9544 | |
Gregory Francis Murphy, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 275 Bethesda Dr, Greenville, NC 27834 Phone: 252-752-5077 Fax: 525-752-9544 |